Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling
- PMID: 16682246
- DOI: 10.1016/j.biocel.2006.01.009
Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling
Abstract
Epithelial ovarian cancer, the fourth leading cause of cancer deaths in American women, is currently classified by surgical and histologic appearance. However, the predictive value of this classification is limited. The risk of epithelial ovarian cancer increases with the number of ovulatory events. It is now thought that different ovarian tumors are derived from a single ovarian surface epithelial precursor cell with the degree and pattern of differentiation determined by combinatorial expression of homeobox genes normally involved in differentiation of the female genital tract. This aberrant differentiation occurs in association with histology-specific genomic aberrations, genomic instability, and resultant chromosomal changes, and may be triggered by prolonged abnormal or excessive exposure of surface epithelial cells to autocrine/paracrine stimulation by sex steroids and other growth factors. As the disease progresses, activation of kinase pathways and continued abnormal autocrine/paracrine stimulation contribute to genomic instability but also identify potential targets for novel therapeutic intervention.
Similar articles
-
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.Cancer. 2006 Oct 15;107(8):1801-11. doi: 10.1002/cncr.22195. Cancer. 2006. PMID: 16983702
-
Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway.Endocr Relat Cancer. 2009 Mar;16(1):179-88. doi: 10.1677/ERC-07-0238. Epub 2008 Nov 20. Endocr Relat Cancer. 2009. PMID: 19022848
-
Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.Gynecol Oncol. 2007 Jan;104(1):168-75. doi: 10.1016/j.ygyno.2006.07.007. Epub 2006 Aug 28. Gynecol Oncol. 2007. PMID: 16935322
-
Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.Cells Tissues Organs. 2007;185(1-3):85-94. doi: 10.1159/000101307. Cells Tissues Organs. 2007. PMID: 17587812 Review.
-
Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.Int Rev Cytol. 2005;242:1-54. doi: 10.1016/S0074-7696(04)42001-4. Int Rev Cytol. 2005. PMID: 15598466 Review.
Cited by
-
Molecular targeted therapy in ovarian cancer: what is on the horizon?Drugs. 2011 May 28;71(8):947-67. doi: 10.2165/11591740-000000000-00000. Drugs. 2011. PMID: 21668036 Review.
-
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.J Oncol. 2009;2009:581939. doi: 10.1155/2009/581939. Epub 2010 Jan 17. J Oncol. 2009. PMID: 20145720 Free PMC article.
-
DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.J Biol Chem. 2009 Jul 31;284(31):20593-601. doi: 10.1074/jbc.M109.021477. Epub 2009 Jun 4. J Biol Chem. 2009. PMID: 19497851 Free PMC article.
-
MicroRNA and ovarian cancer.Histol Histopathol. 2008 Sep;23(9):1161-9. doi: 10.14670/HH-23.1161. Histol Histopathol. 2008. PMID: 18581287 Free PMC article. Review.
-
Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1.J Exp Clin Cancer Res. 2016 Jan 21;35:15. doi: 10.1186/s13046-016-0294-2. J Exp Clin Cancer Res. 2016. PMID: 26791264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials